{"entity": "publication", "iuid": "efeaf9dabb9b42808f9557209e9029c1", "timestamp": "2026-08-23T09:26:25.606Z", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/efeaf9dabb9b42808f9557209e9029c1.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/efeaf9dabb9b42808f9557209e9029c1"}}, "title": "Exploratory insights from the immuno-oncology hollow fiber assay: A pilot approach bridging In Vitro and In Vivo models.", "authors": [{"family": "Selvin", "given": "Tove", "initials": "T"}, {"family": "Berglund", "given": "Malin", "initials": "M"}, {"family": "\u00c5kerstr\u00f6m", "given": "Anders", "initials": "A"}, {"family": "Zia", "given": "Marco", "initials": "M"}, {"family": "Rudfeldt", "given": "Jakob", "initials": "J"}, {"family": "Jarvius", "given": "Malin", "initials": "M"}, {"family": "Larsson", "given": "Rolf", "initials": "R"}, {"family": "Andersson", "given": "Claes R", "initials": "CR"}, {"family": "Frykn\u00e4s", "given": "M\u00e5rten", "initials": "M"}], "type": "journal article", "published": "2024-12-00", "journal": {"title": "SLAS Technol", "issn": "2472-6311", "volume": "29", "issue": "6", "pages": "100232", "issn-l": null}, "abstract": "To facilitate the translation of immunotherapies from bench to bedside, predictive preclinical models are essential. We developed the in vivo immuno-oncology Hollow Fiber Assay (HFA) to bridge the gap between simpler cell-based in vitro assays and more complex mouse models for immuno-oncology drug evaluation. The assay involves co-culturing human cancer cell lines or primary patient-derived cancer cells with human immune cells inside semipermeable hollow fibers. Implanted intraperitoneally in mice, the fibers captured treatment-induced immune cell-mediated cancer cell killing following treatments with aCD3 and/or IL-2, demonstrating the feasibility of the assay. Traditional models require lengthy observation periods to monitor tumor growth and treatment response. The immuno-oncology HFA enables a rapid initial in vivo evaluation of immunological agents on cancer and immune cells of human origin, addressing two of the 3Rs - reduction and refinement - in animal research.", "doi": "10.1016/j.slast.2024.100232", "pmid": "39638255", "labels": [], "xrefs": [{"db": "pii", "key": "S2472-6303(24)00114-6"}], "notes": [], "created": "2026-08-21T11:29:17.061Z", "modified": "2026-08-21T11:29:17.073Z"}